Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results be...
Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report
About this item
Full title
Author / Creator
Publisher
Athens: Spandidos Publications
Journal title
Language
English
Formats
Publication information
Publisher
Athens: Spandidos Publications
Subjects
More information
Scope and Contents
Contents
Patients with non-small cell lung cancer (NSCLC) are often positive for oncogenic driver mutations, such as EGFR, ALK, BRAF, RET and MET exon 14 skipping mutations (METex14 skipping). Recently, METex14 skipping has become a functional biomarker for NSCLC with the approval of MET kinase inhibitors. Tepotinib is an oral MET kinase inhibitor. Its over...
Alternative Titles
Full title
Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10204052
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10204052
Other Identifiers
ISSN
2049-9450
E-ISSN
2049-9469
DOI
10.3892/mco.2023.2645
